Stock ZLD ZELIRA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 10:57:22 2024-04-15 pm EDT 		5-day change 1st Jan Change
0.72 AUD +1.41% Intraday chart for Zelira Therapeutics Limited +2.86% -20.00%
Apr. 15 Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme MT
Feb. 22 Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Business Summary

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter [OTC] products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Sales per Business

AUD in Million2022Weight2023Weight Delta
Cannabinoid-based Medicines
100.0 %
2 100.0 % 0 100.0 % -80.45%

Sales per region

AUD in Million2022Weight2023Weight Delta
United States
70.9 %
1 95.7 % 0 70.9 % -85.51%
Australia
29.1 %
0 4.3 % 0 29.1 % +31.03%

Managers

Managers TitleAgeSince
Oludare Odumosu CEO
 Chief Executive Officer - 19-11-27
Rahul Ganesan DFI
 Director of Finance/CFO - -
Greg Blake BRD
 Director/Board Member - 19-12-31
Timothy Slate BRD
 Director/Board Member - 16-10-19

Members of the board

Members of the board TitleAgeSince
Osagie Imasogie CHM
 Chairman 62 19-11-27
Timothy Slate BRD
 Director/Board Member - 16-10-19
Oludare Odumosu CEO
 Chief Executive Officer - 19-11-27
Greg Blake BRD
 Director/Board Member - 19-12-31
Donna O’Donnell BRD
 Director/Board Member - 23-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 11,347,155 5,820,324 ( 51.29 %) 0 51.29 %

Shareholders

NameEquities%Valuation
Evolve Funds Group, Inc.
0.009932 %
1,127 0.009932 % 515 $

Company contact information

Zelira Therapeutics Ltd.

101 St George’s Terrace Level 3

6000, Perth

+61 8 6558 0886

http://zeliratx.com
address Zelira Therapeutics Limited(ZLD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ZELIRA THERAPEUTICS LIMITED Stock Zelira Therapeutics Limited
-20.00% 5.21M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.34% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.31% 96.56B
ARGENX SE Stock argenx SE
+2.15% 22.61B
BIONTECH SE Stock BioNTech SE
-16.72% 21.18B
GENMAB A/S Stock Genmab A/S
-4.22% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.75% 16.53B
BEIGENE, LTD. Stock BeiGene, Ltd.
-23.26% 14.46B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-0.02% 13.25B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+22.69% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZLD Stock
  4. Company Zelira Therapeutics Limited